HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mejia, A. A. Articles by Watanuki, S. Search for Related Content PubMed PubMed Citation Articles by Mejia, A. A. Articles by Watanuki, S.

Estimation of Absorbed Doses in Humans Due to Intravenous Administration of Fluorine-18-Fluorodeoxyglucose in PET Studies

Division of Radiation Protection and Division of Nuclear Medicine, Cyclotron and Radioisotope Center of Tohoku University, Aramaki-Aoba, Japan

Correspondence: For reprints contact: Prof. Takashi Nakamura, Cyclotron and Radioisotope Center, Tohoku University, Aramaki-Aoba, Sendai 980, Japan.

ABSTRACT

Radiation absorbed doses due to intravenous administration of fluorine-18-fluorodeoxyglucose in positron emission tomography (PET) studies were estimated in normal volunteers. The time-activity curves were obtained for seven human organs (brain, heart, kidney, liver, lung, pancreas, and spleen) by using dynamic PET scans and for bladder content by using a single detector. These time-activity curves were used for the calculation of the cumulative activity in these organs. Absorbed doses were calculated by the MIRD method using the absorbed dose per unit of cumulated activity, "S" value, transformed for the Japanese physique and the organ masses of the Japanese reference man. The bladder wall and the heart were the organs receiving higher doses of 1.2 x 10^–1 and 4.5 x 10^–2 mGy/MBq, respectively. The brain received a dose of 2.9 x 10^–2 mGy/MBq, and other organs received doses between 1.0 x 10^–2 and 3.0 x 10^–2 mGy/MBq. The effective dose equivalent was estimated to be 2.4 x 10^–2 mSv/MBq. These results were comparable to values of absorbed doses reported by other authors on the radiation dosimetry of this radiopharmaceutical.

This article has been cited by other articles:

				P. Zanotti-Fregonara, C. Champion, R. Trebossen, R. Maroy, J.-Y. Devaux, and E. Hindie Estimation of the {beta}+ Dose to the Embryo Resulting from 18F-FDG Administration During Early Pregnancy J. Nucl. Med., April 1, 2008; 49(4): 679 - 682. [Abstract] [Full Text] [PDF]

				S. Jakobsen, K. Pedersen, D. F. Smith, S. B. Jensen, O. L. Munk, and P. Cumming Detection of {alpha}2-Adrenergic Receptors in Brain of Living Pig with 11C-Yohimbine J. Nucl. Med., December 1, 2006; 47(12): 2008 - 2015. [Abstract] [Full Text] [PDF]

				T. Beyer, G. Antoch, S. Muller, T. Egelhof, L. S. Freudenberg, J. Debatin, and A. Bockisch Acquisition Protocol Considerations for Combined PET/CT Imaging J. Nucl. Med., January 1, 2004; 45(90010): 25S - 35. [Abstract] [Full Text] [PDF]

				H. Vesselle, J. Grierson, L. M. Peterson, M. Muzi, D. A. Mankoff, and K. A. Krohn 18F-Fluorothymidine Radiation Dosimetry in Human PET Imaging Studies J. Nucl. Med., September 1, 2003; 44(9): 1482 - 1488. [Abstract] [Full Text] [PDF]

				M. T. Hays, E. E. Watson, S. R. Thomas, and M. Stabin MIRD Dose Estimate Report No. 19: Radiation Absorbed Dose Estimates from 18F-FDG J. Nucl. Med., February 1, 2002; 43(2): 210 - 214. [Full Text] [PDF]

				D. A. Mankoff, L. M. Peterson, T. J. Tewson, J. M. Link, J. R. Gralow, M. M. Graham, and K. A. Krohn [18F]Fluoroestradiol Radiation Dosimetry in Human PET Studies J. Nucl. Med., April 1, 2001; 42(4): 679 - 684. [Abstract] [Full Text]